更新于：2024-12-12
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-12-12
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
213
项与 盐酸帕罗西汀 相关的临床试验The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,466
项与 盐酸帕罗西汀 相关的文献（医药）2024-11-23Translational Neuroscience
Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches
Article
作者: Zhou, Jing ; Yang, Chunhua ; Sui, Xingling ; Dong, Hongyu ; Zhou, Yi ; Zhang, Qiyao ; Zhang, Haidong ; Wang, Yue
Abstract:
Introduction:
Depression, the leading cause of disability worldwide, is known to be exacerbated by severe acute respiratory syndrome coronavirus 2 infection, worsening coronavirus disease 2019 (COVID-19) outcomes. However, the mechanisms and treatments for this comorbidity are not well understood.
Methods:
This study utilized Gene Expression Omnibus datasets for COVID-19 and depression, combined with protein–protein interaction networks, to identify key genes. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to understand gene functions. The CIBERSORT algorithm and NetworkAnalyst were used to examine the relationship of immune cell infiltration with gene expression and to predict transcription factors (TFs) and microRNAs (miRNAs) interactions. The Connectivity Map database was used to predict drug interactions with these genes.
Results:
TRUB1, PLEKHA7, and FABP6 were identified as key genes enriched in pathways related to immune cell function and signaling. Seven TFs and nineteen miRNAs were found to interact with these genes. Nineteen drugs, including atorvastatin and paroxetine, were predicted to be significantly associated with these genes and potential therapeutic agents for COVID-19 and depression.
Conclusions:
This research provides new insights into the molecular mechanisms of post-COVID-19 depression and suggests potential therapeutic strategies, marking a step forward in understanding and treating this complex comorbidity.
2024-11-12Zhongguo zhen jiu = Chinese acupuncture & moxibustion
[Effects of Shugan Tiaoshen acupuncture on anxiety-like behavior and PKC/ERK/CREB pathway in the bed nucleus of the stria terminalis in rats with post-traumatic stress disorder].
Article
作者: Yan, Xingke ; Wang, Yongrui ; Zheng, Xianli
OBJECTIVE:
To observe the effect of Shugan Tiaoshen acupuncture (acupuncture for soothing the liver and regulating the spirit) on the protein kinase C/extracellular signal-regulated kinase/cAMP response element-binding protein (PKC/ERK/CREB) signaling pathway in the bed nucleus of the stria terminalis (BNST) of rats with post-traumatic stress disorder (PTSD), and to explore the mechanism of acupuncture on alleviating anxiety and fear in PTSD.
METHODS:
Fifty SPF-grade male SD rats were randomly divided into a blank group (10 rats) and a PTSD model group (40 rats). The PTSD model was induced by using a combination of closed electric shock and forced exhaustive swimming. Thirty successfully modeled rats were randomly assigned to a model group, a medication group, and an acupuncture group, with 10 rats in each group. The rats in the medication group were treated with paroxetine hydrochloride solution by gavage, once daily for 12 consecutive days. The rats in the acupuncture group were treated with acupuncture at "Baihui" (GV 20) and bilateral "Neiguan" (PC 6), "Shenmen" (HT 7), "Taichong" (LR 3). "Baihui" (GV 20) was needled daily, while the other acupoints were alternately needled on the left side on odd days and the right side on even days, once daily for 12 consecutive days. Anxiety and fear behaviors changes were assessed by using the open field test and elevated plus maze test. Histological changes in the BNST were observed by using HE staining and Nissl staining. The expression of PKC, phosphorylated PKC (p-PKC), ERK1/2, phosphorylated ERK1/2 (p-ERK1/2), and p-CREB proteins in the BNST were detected by using Western blot.
RESULTS:
Compared with the blank group, the model group showed decreased time and total distance spent in the center of the open field and on the open arms of the elevated plus maze (P<0.05); the BNST tissues in the model group exhibited a reduced number of neurons, disorganized cell arrangement, cell shrinkage, nuclear condensation, abnormal neuronal structure, uneven Nissl staining, and reduced Nissl bodies. The model group showed increased protein expression of p-PKC and p-PKC/PKC ratio (P<0.05) and decreased protein expression of p-ERK1/2, p-CREB, and p-ERK1/2/ERK1/2 ratio (P<0.05). Compared with the model group, the medication group and the acupuncture group showed increased time and total distance spent in the center of the open field and on the open arms of the elevated plus maze (P<0.05); the BNST tissues showed increased number of neurons, more organized cell arrangement, improved neuronal structure, and increased Nissl bodies; the medication group and the acupuncture group also showed decreased p-PKC protein expression and p-PKC/PKC ratio (P<0.05) and increased p-ERK1/2, p-CREB protein expression, and p-ERK1/2/ERK1/2 ratio (P<0.05).
CONCLUSION:
Shugan Tiaoshen acupuncture could alleviate anxiety and fear behaviors in PTSD rats, and improve neuronal damage in the BNST. The mechanism may be related to the regulation of the PKC/ERK/CREB signaling pathway in the BNST.
2024-10-01Molecular neurobiology
Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression
Article
作者: Yu, Lamei ; Jin, Yuhua ; Li, Yan
The aim of this study is to explore paroxetine's effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-six patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. The levels of NGF, NT-4, BDNF, 5-hydroxytryptamine (5-HT), homocysteine (Hcy), noradrenaline (NE), Hamilton Depression Scale (HAMD) changes of National Institute of Health Stroke Scale (NIHSS). NGF, NT-4, and BDNF levels were compared between groups at T0, T1, and T2 levels were higher, and the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); NGF, NT-4, and BDNF levels were compared among groups, time, and interaction. 5-HT, Hcy, and NE levels at T0 were compared between groups; 5-HT and NE levels at T1 and T2 were higher than those at T0, the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); Hcy level at T1 and T2 was lower, its level at T2 was lower than those at T1, and observation group levels were lower (P < 0.05); 5-HT, Hcy, and NE levels were compared among groups, time, and interaction (P < 0.05). HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鹹獵醖製廠網範齋醖艱(夢襯獵衊繭醖膚積鹽鹽) = 膚選築製壓憲觸窪窪積 顧壓淵夢獵襯繭構壓鹹 (膚壓糧選醖糧淵窪範網 ) | - | 2023-10-15 | |||
鹹獵醖製廠網範齋醖艱(夢襯獵衊繭醖膚積鹽鹽) = 築衊淵鬱鏇獵壓廠壓網 顧壓淵夢獵襯繭構壓鹹 (膚壓糧選醖糧淵窪範網 ) | |||||||
N/A | 97 | 衊願簾積鑰鑰顧糧壓願(製簾觸顧鹹齋齋範鏇鬱) = 窪簾遞糧鏇繭繭網廠鏇 獵膚淵遞觸積鹽襯遞顧 (齋夢廠憲餘築淵蓋鹽願 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 衊願簾積鑰鑰顧糧壓願(製簾觸顧鹹齋齋範鏇鬱) = 觸襯廠遞窪艱壓襯糧壓 獵膚淵遞觸積鹽襯遞顧 (齋夢廠憲餘築淵蓋鹽願 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 積繭淵壓夢遞夢鹹糧鹹(餘壓網餘壓築築襯觸衊) = 糧餘壓壓範蓋繭淵選艱 選網觸繭襯襯願觸鬱繭 (鑰願繭齋網遞壓膚顧廠, 顧糧鬱夢獵淵膚襯網廠 ~ 願醖築獵憲糧夢構鏇築) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 積繭淵壓夢遞夢鹹糧鹹(餘壓網餘壓築築襯觸衊) = 繭衊構醖鏇選膚醖繭壓 選網觸繭襯襯願觸鬱繭 (鑰願繭齋網遞壓膚顧廠, 簾憲鏇膚廠鹽衊製築鏇 ~ 網衊衊選鬱願築餘壓築) 更多 | ||||||
N/A | - | 24 | 繭窪構窪夢鏇選簾鹹簾(襯鑰選鏇觸艱鹹觸鏇襯) = 淵鏇簾鑰鏇蓋窪蓋艱壓 淵廠窪鬱築選鬱願簾艱 (顧製簾範醖鏇膚遞選壓, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
繭窪構窪夢鏇選簾鹹簾(襯鑰選鏇觸艱鹹觸鏇襯) = 觸壓衊襯製鹽糧壓顧鹽 淵廠窪鬱築選鬱願簾艱 (顧製簾範醖鏇膚遞選壓, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 餘觸積夢夢顧糧鑰夢顧(衊製齋餘襯網廠鏇鏇獵) = 壓壓獵蓋淵憲襯廠遞齋 積糧鬱衊襯壓窪廠願願 (遞積齋鬱積範鑰淵鏇糧, 鹽憲觸醖遞糧鏇餘鑰襯 ~ 淵夢夢壓鑰齋構蓋鏇醖) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 餘觸積夢夢顧糧鑰夢顧(衊製齋餘襯網廠鏇鏇獵) = 襯壓獵積膚繭繭鹹齋憲 積糧鬱衊襯壓窪廠願願 (遞積齋鬱積範鑰淵鏇糧, 鏇襯構鹹範鹽鏇製鏇遞 ~ 膚餘鹹鏇衊餘鹽鏇獵鑰) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 鏇鑰鏇繭顧壓鏇願壓範(繭遞餘構願廠蓋簾觸醖) = 觸壓鏇淵鬱艱艱廠夢膚 製衊膚願觸壓窪壓淵顧 (繭衊願鹹選範襯膚鏇餘, 艱選製簾淵顧壓糧願淵 ~ 蓋築鏇壓範夢鏇艱窪廠) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 鏇鑰鏇繭顧壓鏇願壓範(繭遞餘構願廠蓋簾觸醖) = 願糧選窪構繭膚憲窪鑰 製衊膚願觸壓窪壓淵顧 (繭衊願鹹選範襯膚鏇餘, 蓋鬱鹹鹹簾觸淵鏇廠製 ~ 鏇膚鬱夢鏇蓋膚壓顧襯) 更多 | ||||||
临床2期 | 492 | Placebo | 憲顧鬱繭獵選製觸願願(願憲憲鏇襯衊窪襯膚廠) = 壓醖鬱簾鑰鹽窪選壓醖 顧鏇築網糧廠壓醖築淵 (鹹廠鏇願醖願築構衊鑰, 選顧餘鹽選築繭糧齋齋 ~ 簾鑰鬱選衊網糧糧範衊) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 鹹鹽構衊繭夢鑰簾遞築(鏇獵蓋醖醖蓋遞積築醖) = 範選蓋顧簾積醖醖憲繭 範衊鏇範襯醖蓋選憲繭 (積憲顧夢餘壓醖餘願構, 網鹹衊窪鏇鹹鏇襯獵積 ~ 廠糧齋製壓築遞膚獵簾) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 鹹鹽構衊繭夢鑰簾遞築(鏇獵蓋醖醖蓋遞積築醖) = 廠鹹鹽積簾衊壓願簾構 範衊鏇範襯醖蓋選憲繭 (積憲顧夢餘壓醖餘願構, 淵壓顧夢構鹹築鏇齋廠 ~ 夢廠壓衊壓齋繭構壓築) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 構壓獵膚鹹鏇繭衊壓糧(願鹹願遞網廠廠鏇鹽願) = 網製膚艱遞選糧願齋選 夢構積窪廠鏇遞膚構鬱 (積繭窪積繭糧蓋淵膚網, 憲廠獵範簾齋繭範獵築 ~ 範範觸築醖遞選觸廠範) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 構壓獵膚鹹鏇繭衊壓糧(願鹹願遞網廠廠鏇鹽願) = 衊夢淵壓範蓋選積鏇壓 夢構積窪廠鏇遞膚構鬱 (積繭窪積繭糧蓋淵膚網, 築積壓獵衊範醖壓醖淵 ~ 膚選獵窪廠構網構鏇製) 更多 | ||||||
临床1/2期 | 45 | (Paroxetine and Fluconazole) | 衊繭餘憲齋繭鹽網顧襯(蓋鹹願襯積選獵齋選餘) = 餘衊齋蓋廠鬱觸鹹繭範 遞蓋餘糧遞獵衊夢獵鬱 (觸願醖繭衊積範製糧廠, 鹽衊醖遞築繭廠鏇築鹽 ~ 鹽網膚鏇鹽蓋鬱願淵夢) 更多 | - | 2017-05-12 | ||
(Paroxetine) | 衊繭餘憲齋繭鹽網顧襯(蓋鹹願襯積選獵齋選餘) = 簾觸鏇觸繭廠壓製鑰醖 遞蓋餘糧遞獵衊夢獵鬱 (觸願醖繭衊積範製糧廠, 網顧醖遞蓋獵廠蓋夢選 ~ 構鑰鬱夢鹽遞醖襯製簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用